N
Google TrendLAMINE YAMAL (5000+) — "You want to play for Morocco?": Getafe defender provokes Yamal with shocking words
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:lamine yamal5000+thélyson orélien500+adeyemi500+abdulrahman alfozan500+pope francis500+delaware vs middle tennessee prediction500+bayern de múnich200+pablo torre200+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Engineering anti-BCMA CAR" (30 stories)

Top Headline Story

StockWatch: Caribou Plunges as It Pursues Strategic Alternatives
Lead StoryGenetic Engineering and Biotechnology Newsmarkets
1d ago

StockWatch: Caribou Plunges as It Pursues Strategic Alternatives

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxOQW02VDdDSG1JbkhHZFFkQVJEdTVvOGJCZ1VZRmRub0c3VVJsXzRGXzduMjBxZU1RQUZNUlFYcE4xaVAwM2NRdGpmTzljZFlwblVnQUVpbVhXOTlnRW9adWg0cTZfVVltTFpZbndNNVVBMnl4MUY1a0hzZ1N0SmdzRDBvbkR5SFVvejd3WURLaGU3RkFQRnRJVXRMbnVmbF90T1R0X1lhTEsyc1lPS3Uzc3EtTQ?oc=5" target="_blank">StockWatch: Caribou Plunges as It Pursues Strategic Alternatives</a>  <font color="#6f6f6f">Genetic Engineering and Biotechnology News</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
5000+29m ago

lamine yamal

"You want to play for Morocco?": Getafe defender provokes Yamal with shocking words

Filter stories
500+29m ago

thélyson orélien

Acclaimed Author Denies Using A.I. but Admits Plagiarism

Filter stories
500+29m ago

adeyemi

Licensable picture: Galatasaray v Barcelona - UEFA Champions League

Filter stories
500+39m ago

abdulrahman alfozan

Saudi national OpenAI employee arrested after 'sophisticated recording device' planted in office

Filter stories

Search Results for "Engineering anti-BCMA CAR"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study
Naturegeneral

In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1SVmxfSmNWQmJtR0stZGZXN2pxWUlsWFQzdm1WdE9heDNmRkNxd0lSdkpLVmlBN0M1d0lGM1REbTFwcmg3TF9VTy02OElMRGJLeXVGaENHUE9VOGV5Y05B?oc=5" target="_blank">In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Engineering Soluble Recombinant BCMA for Ide‐Cel Labeling - Nguyen - 2026 - European Journal of Immunology
Wiley Online Libraryworld

Engineering Soluble Recombinant BCMA for Ide‐Cel Labeling - Nguyen - 2026 - European Journal of Immunology

<a href="https://news.google.com/rss/articles/CBMiakFVX3lxTE8tNXBmeVY1WlFtNmg0ai0yNk5sT1dTOEV5OUhqZWFkc2pmd0Z6TFl1b0sxQVZ1V0NyZ0lnWE9OaUFJdmFZaVhtSjhadWZQR05NVFM5bk5YZjItOExBVXdneGZFczdoQVVMdUE?oc=5" target="_blank">Engineering Soluble Recombinant BCMA for Ide‐Cel Labeling - Nguyen - 2026 - European Journal of Immunology</a>  <font color="#6f6f6f">Wiley Online Library</font>

Read Full StoryMore like this
FDA Grants RMAT Designation to Allogeneic CAR T for R/R Multiple Myeloma
Targeted Oncologygeneral

FDA Grants RMAT Designation to Allogeneic CAR T for R/R Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxNcVhvOEp2b3BsQUQtRE1jUmhSS2VEcFdubHpMdzg3a3NURmZWa0JMMkNOOHo5RXVTSE1kWG9nTVNLUHZBY1JCbExEMGpZV2ItNmxIOEYwS0pMUl84ZXB1V2FUMlBMejhTNG16cjEyNFZleVFlZVlqek5LQVR6cmd1aTRjWGdHaU1kTDdPZzNxMWVJbTJWeXBINWNfRVZhUEp2UFZCUlp3d18?oc=5" target="_blank">FDA Grants RMAT Designation to Allogeneic CAR T for R/R Multiple Myeloma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
What ESO-T01 Tells Us About the Next Frontier in Multiple Myeloma
CancerNetworkgeneral

What ESO-T01 Tells Us About the Next Frontier in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPM2FmeFRJM29jVWhUUXo1dkRHbWFNZzV4SVFFb09GM3MtcUNQTHo4Wk9CZFdVaDVla1ZIZ3RTQzZJTEVqTU1ZVEdNRHdOVTZVSnRHNmkxaGNaMkh0V0VEMk1NMzY0ZHpaaGVVemhUcmdwa1FqLU82ME5peEFxdGcyTW4xQTdjUW1RblZ5WkctWGF0ajJObnJVc0FTM1ZpeXpEbGc?oc=5" target="_blank">What ESO-T01 Tells Us About the Next Frontier in Multiple Myeloma</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
In Vivo CAR T Causes Serious Toxicities in All Patients of Early Trial
Inside Precision Medicinegeneral

In Vivo CAR T Causes Serious Toxicities in All Patients of Early Trial

<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxONHFIdVlZajhZTzBZTnlheE95T0MyR2NSRUF6VVNHNlJjWVgtM0ZVX1ZSWHk2RzFxRUZCX0RnQVdFSEJDNnQzcFliQ3dmUHg2TE91blpiT3ZicXdvbnlGQmRzOWdtb2VDWW5TdnljVlRib2JhWFdGSTNWZ0lRaVZaaU9IcnJrMlZhRmprZEwycVN0Q0E1NElTUnVKT3l3UGJYanEzaG9ObVExRVNQdHRMTllrMWEzcUNNaXNrZ09xMlMyRllEVEE?oc=5" target="_blank">In Vivo CAR T Causes Serious Toxicities in All Patients of Early Trial</a>  <font color="#6f6f6f">Inside Precision Medicine</font>

Read Full StoryMore like this
Designing universal T cell therapies: strategies to evade natural killer cells
Frontiersworld

Designing universal T cell therapies: strategies to evade natural killer cells

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPUUJiY3NPc0g1S1ZyTXdUTzRGY3ZSSGZIYlRFT1hqa1Mzb0wyNC05Vmw0SUtMZF84X0ZuSnRrYXJLTnlqSWhPVmM4SVh5a0JobFVxcUhWMjJqYjljakgzaUJhZS1NNUdYNWRXbzFCNHlfUlFzLV9hS1dXYkZnUUxianBmU2g1V1drSnJMbzZaV05NUQ?oc=5" target="_blank">Designing universal T cell therapies: strategies to evade natural killer cells</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation
Naturegeneral

Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5xakdudDBzSS1Sckc1MjV4MURQcUpROHQ3TkVVTTZmWFZ2VnJ4aDcwcWFEWHJSYUZHS3NLaE1RWks0V0RMWWQyZkNKYUZVVlpoTk1kVDItaVdJal9xMUlR?oc=5" target="_blank">Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Gene Therapy-Induced CAR T Cells for Myeloma Could Alter Treatment Landscape
MedPage Todaygeneral

Gene Therapy-Induced CAR T Cells for Myeloma Could Alter Treatment Landscape

<a href="https://news.google.com/rss/articles/CBMic0FVX3lxTE8ySER6LXhpb3F0Y1NxTmVDN1hZaWVhX2RiZkJZbWU5M2pUanR3LWxWUktFd2JPMFhCdEZ0X0hMTmdlSVRUcmVNRmxsaVkyQjdmejdTTmZ5U281ZU83Q0xDeEVtOG9Pa1hlVTduZDRvVTFsWDg?oc=5" target="_blank">Gene Therapy-Induced CAR T Cells for Myeloma Could Alter Treatment Landscape</a>  <font color="#6f6f6f">MedPage Today</font>

Read Full StoryMore like this
IASO Bio acquires MediSix to expand CAR-T reach into T-cell malignancies
AllScigeneral

IASO Bio acquires MediSix to expand CAR-T reach into T-cell malignancies

<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxObDlaZ2s3V1FMSDBhZHBETkpsb1hoZjFhNVpIRExTTC1rZW9YcjVzelB1WjExUGlXQ204SW1HczJxX1Myc29iMkVsVVBlRjVVYnAyMGxzNVh3cFZ2TDZxTk1OZkFkT19PU2hCb1dSVDBCbHpnY29UdW4wRTAxZE5XcmtIeHc3aVVOUWh5WW5hU0I3bVYy?oc=5" target="_blank">IASO Bio acquires MediSix to expand CAR-T reach into T-cell malignancies</a>  <font color="#6f6f6f">AllSci</font>

Read Full StoryMore like this
In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma
The Lancetgeneral

In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxOQVJDVU9KMlpjYzlta1A2ZnRLNHZiUXNmTzhkT3RDNUpEYW8yMFJXaTNNdHdYajJxVVp5TVd5MUxtd2lWVUg2TEQwT1JCTnBKaGl0QVdJa295aUNqVURjN1FDMlFrV1RBaVJLeXlGa3c0TEF3dFVpN1h2a3c3bFM5NktxcEhDQWQtWV9r?oc=5" target="_blank">In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma</a>  <font color="#6f6f6f">The Lancet</font>

Read Full StoryMore like this
Cell Publishes Breakthrough Research Results of IASO Bio's Anti-BCMA CAR-T Equecabtagene Autoleucel in Autoimmune Disease Multiple Sclerosis
PR Newswireworld

Cell Publishes Breakthrough Research Results of IASO Bio's Anti-BCMA CAR-T Equecabtagene Autoleucel in Autoimmune Disease Multiple Sclerosis

<a href="https://news.google.com/rss/articles/CBMioAJBVV95cUxNMW1WdzFIeGI4TlBEUGNPRlFjYjhzU3l6dVEtZTFKYTI2RWR5UGQ0emJYTjNTYkMwOEJYRDFFUkZ4M29NdzhrMFFORTBGdDFYOWRlYXJiMHQ5SFgxZ0xIcXFHUENZSzczV3NqVWtSLVh2UHhqSk1xQWxqVW1SYm1tYzF4WnN5alQzMlhHZ2JFUWlmSm5tZEY1TUY4eEtPaDg2eEFLbl9UVVhqbUprSW5wMjJWVldGc2dGcGh1dXVCZV92bkJ5TWo1SnpWNzNibUxPV0g0Szc4NGlneTZ2V2dMVmdZdE1tSVhBanZmTGlxWTRWTGtsQ0NOQzU3ck1SZFVFTzVjS21zQk82TTZwSzFiLUtlay1LWVctak9UMXBQcko?oc=5" target="_blank">Cell Publishes Breakthrough Research Results of IASO Bio's Anti-BCMA CAR-T Equecabtagene Autoleucel in Autoimmune Disease Multiple Sclerosis</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Sequence and structural determinants of efficacious de novo chimaeric antigen receptors
Naturegeneral

Sequence and structural determinants of efficacious de novo chimaeric antigen receptors

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE4zaTFfQlBBMHpVMVIzb0xFdVlaTjdoNWJqcndiSmwzRFY1dkdnbTZUR29XSHh4Vjdwa05ETkVObVF5RGJWSnNqNHZjRFoydDhkeDItMVF0aDFNZDZrb2Rj?oc=5" target="_blank">Sequence and structural determinants of efficacious de novo chimaeric antigen receptors</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody
Naturegeneral

Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBGMmNLejNGWkdwakF1T2NXdGdFd0ZyZ2VTamFfMmJ5WWtRRVFIZFFOZm82WFhRR1l5WEJwUmk0VUlnaHJENHJBam5qOTdkT1RlS0dwMHFyaTBLTUdQQi1R?oc=5" target="_blank">Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma
Natureworld

Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1ReG1rMnNWWHlxaDFvRnFxZFFvQzRvbzJDTk8xOWUtRGNrS3ZobEdzR29MejZOdFFjQVRaMWtHYlYzUndQQzlUdkcyc0FuRjlLYUlKd3lKLVo2QmhGTmdN?oc=5" target="_blank">Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
In vivo site-specific engineering to reprogram T cells
Naturegeneral

In vivo site-specific engineering to reprogram T cells

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5GcGRFQk9PM1N2TXZUa2ZTTVFJbENHN2RXeDR1LTY3anJ4bFlITHB2LTFHNUZtaFlGNW0xREFEaU9vNUp3ampFUll6eFdNNm90YXlWSXNGNkJ3aTA1ckc4?oc=5" target="_blank">In vivo site-specific engineering to reprogram T cells</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
CAR-T cell therapy in Multiple Myeloma: current status and future challenges | Blood Cancer Journal
Naturegeneral

CAR-T cell therapy in Multiple Myeloma: current status and future challenges | Blood Cancer Journal

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBpNVJMOWptcmpPV3BBRG5QeERCellyMl9DQ2JpZ2dMY0VqanNPVFBSeUdyWDRsc09EWUVzNS1KZE5qYm1weXlVNExuWU1JQ040SXE0NXBIeWxtOEdVTFRV?oc=5" target="_blank">CAR-T cell therapy in Multiple Myeloma: current status and future challenges | Blood Cancer Journal</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Immune cell engineering for cancer therapy 2024
Natureworld

Immune cell engineering for cancer therapy 2024

<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE85TkNOWEhmWXMtS0pySlllZFlCYU5EdmE4LU5aTGx5N01KanhMRXZCM3NnTzRfaUdxZGdPb0NzVG1FSzRJbUZHOTY0X25Rck5NZHJPRXZSNUs?oc=5" target="_blank">Immune cell engineering for cancer therapy 2024</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Engineering T cells with a membrane-tethered version of SLP-76 overcomes antigen-low resistance to CAR T cell therapy
Naturegeneral

Engineering T cells with a membrane-tethered version of SLP-76 overcomes antigen-low resistance to CAR T cell therapy

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5Bdm5jX2trNDZXaVl1UUt2ZXpkQWVuazVtNXphVmZwWmNTU29QRkw3Tmd1b2lTQWF4bTdZY013Y0RuVUhIUjBvRnloVl9xc2d1RU9RbU9BVjNOQ2lNR2pN?oc=5" target="_blank">Engineering T cells with a membrane-tethered version of SLP-76 overcomes antigen-low resistance to CAR T cell therapy</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
CAR T cell therapy beyond cancer: current status, challenges and future prospects
Naturegeneral

CAR T cell therapy beyond cancer: current status, challenges and future prospects

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE43WVRRMkY3elBIcnp0TUJpV01HNEpabVNXcDY0WldTN3NEbk1faDNmWDdCdHVBNGtkOHlveVJwMnJ3b0dURUVvWV9rLVBKUzhsOVpmVU5LQ2tBNTA5ZVpN?oc=5" target="_blank">CAR T cell therapy beyond cancer: current status, challenges and future prospects</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma
Naturegeneral

Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma

<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTFBaaTFyX0g1OWp3WVp3SmZxdTF2dmNpaHVpZEZGSks0VEtfU0l0ZFFDajNyM3BDQmVLTG5CaDBaWUE2NmRHZjUyYnFWdWdFTmJtNm5xbE9WUW9GNkRwM2c?oc=5" target="_blank">Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
NEJMgeneral

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE9kZlcyWnFLM0NuRDUzbmxIbk1wQXZZQzlIVE15WWUxUGNJUnduM3VLN1pWdTBYSmR0QUQzdTRBTGE1Z1ZuYlFZcVZ2YUttTXVaa25KTnBRM01iV19JQkc4MA?oc=5" target="_blank">Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma</a>  <font color="#6f6f6f">NEJM</font>

Read Full StoryMore like this
CAR‐T cells in the treatment of multiple myeloma: an encouraging cell therapy
Frontiersgeneral

CAR‐T cells in the treatment of multiple myeloma: an encouraging cell therapy

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPVy15aVdRSzZWLU5XclFEeUVrWkRDV21NS1RYT0NZRjlUcWxTSUxSQl9iRGJHekZvMUJicUNNaHg1RVhydDFrd0NyUktreGVGbkU0ZE56dGdlMENaX29ZTVFEMG5xMTJwOTNFZUg1aWxpS0U1b095VUdvTTVjTDgtRDVudmZFN1lPOTg0UXRxbzN1dw?oc=5" target="_blank">CAR‐T cells in the treatment of multiple myeloma: an encouraging cell therapy</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
Naturegeneral

Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE84ZU9xREJIQ2EzSVI5ZVFiRXFiN05IUVhyT0lRUnJobFItMl9tQlZLWnJuRnVVUFFIN2s5dk1MQm1EaDhZQW1IWlphU2RjdGFDTFpzbUdHZXQwSmpMdG1V?oc=5" target="_blank">Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Solid tumour CAR-T cells engineered with fusion proteins targeting PD-L1 for localized IL-12 delivery
Naturegeneral

Solid tumour CAR-T cells engineered with fusion proteins targeting PD-L1 for localized IL-12 delivery

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5SRTU1dTZ0Y25tUnJtVUxadTEwZjduNUZldXJWeGF2VUtGblNkbjVaU2tBOTFoRnBRbUdockVZVXAwaWZkZmRWU0FUT2p0Y1lteXY5SHMzRWExQzNkdVo4?oc=5" target="_blank">Solid tumour CAR-T cells engineered with fusion proteins targeting PD-L1 for localized IL-12 delivery</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Transitioning from native to synthetic receptors: broadening T-cell engineering and beyond
Naturegeneral

Transitioning from native to synthetic receptors: broadening T-cell engineering and beyond

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9Fbnp4VTZkY3F1bFdmVHJkU0Y4Q3FmYTQ5cXVRTG5KUDlKbDR1WkFhV2hISEE4ZXV0YXFzUjFUREdJbnlQSUloU093NGdnN01sT1NsaEdvSHRJRWhtck53?oc=5" target="_blank">Transitioning from native to synthetic receptors: broadening T-cell engineering and beyond</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Engineering CAR-T therapies for autoimmune disease and beyond
Science | AAASworld

Engineering CAR-T therapies for autoimmune disease and beyond

<a href="https://news.google.com/rss/articles/CBMiZ0FVX3lxTE83WXE5QjRjY09QckJtNFFRUk5wZ0RyTkpLUmVYTE5wNlVIcTd3LUpyOHl5ZlRSVzFPalQ4aDE2b25CTHVKN3h6RUQ5SnRNUHU3ZXJHVWVzZmljalBuc0xLY01IN2xWdWs?oc=5" target="_blank">Engineering CAR-T therapies for autoimmune disease and beyond</a>  <font color="#6f6f6f">Science | AAAS</font>

Read Full StoryMore like this
eVLP-mediated CREM editing enhances cytotoxicity of bicistronic IL-15-armored CD19/BCMA dual-target CAR-NK cells
Frontiersgeneral

eVLP-mediated CREM editing enhances cytotoxicity of bicistronic IL-15-armored CD19/BCMA dual-target CAR-NK cells

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxONnBfdUI5UGNUTEM3MVN5b0ZRb1o4czQwZ1BBb1kyU01KcEtzV1R1LUpSQUpldi1NSkI4SFZkMXRXOEx4Vkhib084ckVOVGE2Q05OSDlrbkxWX0VfUk4zN0hqR3JrR2d5NWdGMEllTVkxblBzdGFRakJYUUxfWmQ3cUxFVjJHMXN0Tm9VTGY2cGtCUQ?oc=5" target="_blank">eVLP-mediated CREM editing enhances cytotoxicity of bicistronic IL-15-armored CD19/BCMA dual-target CAR-NK cells</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma
Naturetech

Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE93T0w2N3lwMFZfYU55Z2d5eV82Qk1pSno3UXZHT0xkMWYtOTlBX09UNGVBNGpPYzM4N2VjUzNIRUVDWXhBbE4xdFdQVzVNSnpvT0JDMFh5dE5Ib1dCbFo4?oc=5" target="_blank">Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Design of sensitive monospecific and bispecific synthetic chimeric T cell receptors for cancer therapy
Naturegeneral

Design of sensitive monospecific and bispecific synthetic chimeric T cell receptors for cancer therapy

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBhaGxsd2JpUDNZbEQtc1didUd3Y3N4cGUzRWJxQVZoOWM4eDVfd0RSeEhhd0N3WTdVMTNYeUpJU045TmVxeXVkdVoxeC1UeWk4Q1Y2OXF5UFluN1JaQ2pF?oc=5" target="_blank">Design of sensitive monospecific and bispecific synthetic chimeric T cell receptors for cancer therapy</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
"Engineering anti-BCMA CAR" — Live Google News Trends & Headlines